William Oh

Alıntı yapanlar

	Hepsi	2020 yılından bugüne
Alıntılar	26860	10722
h-endeksi	84	49
i10-endeksi	270	152

2400

1200

600

1800

2001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025157 242 325 376 517 488 637 594 580 726 895 1048 1016 1198 1206 1272 1313 1532 1448 1753 2204 2307 2038 2115 239

Genel erişim

Tümünü görüntüle

92 makale

13 makale

genel erişime açık olanlar

genel erişime açık olmayanlar

Finansman sağlayan kuruluşun getirdiği zorunluluğa dayalı olarak

Katkıda bulunan yazarlar

Meredith M. Regan, ScDDana-Farber Cancer Institute, Harvard Medical Schoolds.dfci.harvard.edu üzerinde doğrulanmış e-posta adresine sahip
Toni ChoueiriDana-Farber Cancer Institutedfci.harvard.edu üzerinde doğrulanmış e-posta adresine sahip
Judith ManolaBiostatistician, Dana-Farber Cancer Institutejimmy.harvard.edu üzerinde doğrulanmış e-posta adresine sahip
Oliver SartorTulane Universitytulane.edu üzerinde doğrulanmış e-posta adresine sahip
Eric SchadtProfessor of Genetics and Genomic Sciences, Mount Sinai School of Medicinemssm.edu üzerinde doğrulanmış e-posta adresine sahip
Rong ChenDirector of Clinical Genome Informatics & Assistant Professor, Mount Sinai School of Medicinemssm.edu üzerinde doğrulanmış e-posta adresine sahip
Alexander C. SmallDepartment of Urology, Montefiore Medical Centermontefiore.org üzerinde doğrulanmış e-posta adresine sahip
Joaquim BellmuntAssociate Professor of Medicine Harvard Medical Schooldfci.harvard.edu üzerinde doğrulanmış e-posta adresine sahip
Jiaoti HuangDuke University School of medicineduke.edu üzerinde doğrulanmış e-posta adresine sahip
Tomasz M. BeerExact Sciences Corporation and Oregon Health & Science Universityohsu.edu üzerinde doğrulanmış e-posta adresine sahip
Amanda LeiterIcahn School of Medicine at Mount Sinaimssm.edu üzerinde doğrulanmış e-posta adresine sahip
Alberto MartiniAssistant Professor, Director of Research, Dept. of Urology, University of Cincinnatiucmail.uc.edu üzerinde doğrulanmış e-posta adresine sahip
Brian RiniVanderbilt University Medical Centervumc.org üzerinde doğrulanmış e-posta adresine sahip
Phil Febbo, M.D.Veracyte, incveracyte.com üzerinde doğrulanmış e-posta adresine sahip
Carlos Cordon-CardoChair, Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mountmssm.edu üzerinde doğrulanmış e-posta adresine sahip
Michael CooksonProfessor of Urology, University of Oklahomaouhsc.edu üzerinde doğrulanmış e-posta adresine sahip
Madhu MazumdarProfessor of Biostatistics, Icahn School of Medicine at Mount Sinaimountsinai.org üzerinde doğrulanmış e-posta adresine sahip
Clare TempanyBrigham & Women's Hsp/Harvard Medical schoolbwh.harvard.edu üzerinde doğrulanmış e-posta adresine sahip
William Douglas Figg, SrNational Cancer Institutemail.nih.gov üzerinde doğrulanmış e-posta adresine sahip

Takip et

William Oh

Chief Medical Officer, Prostate Cancer Foundation; Clinical Professor of Medicine, Mount Sinai

pcf.org üzerinde doğrulanmış e-posta adresine sahip - Ana Sayfa

AI Prostate Cancer Therapies


Başlık Alıntılara göre sırala Yıla göre sırala Başlığa göre sırala	Alıntı yapanlar Alıntı yapanlar	Yıl
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: results from a large … DYC Heng, W Xie, MM Regan, MA Warren, AR Golshayan, C Sahi, ... Journal of clinical oncology 27 (34), 5794-5799, 2009	2399	2009
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group GJ Bubley, M Carducci, W Dahut, N Dawson, D Daliani, M Eisenberger, ... Journal of Clinical Oncology 17 (11), 3461-3467, 1999	1144	1999
Treatment of muscle‐invasive and advanced bladder cancer in 2020 VG Patel, WK Oh, MD Galsky CA: a cancer journal for clinicians 70 (5), 404-423, 2020	810	2020
Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy MD Galsky, NM Hahn, J Rosenberg, G Sonpavde, T Hutson, WK Oh, ... Journal of clinical oncology 29 (17), 2432-2438, 2011	681	2011
PC3 is a cell line characteristic of prostatic small cell carcinoma S Tai, Y Sun, JM Squires, H Zhang, WK Oh, CZ Liang, J Huang The Prostate 71 (15), 1668-1679, 2011	644	2011
Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer E Mueller, M Smith, P Sarraf, T Kroll, A Aiyer, DS Kaufman, W Oh, ... Proceedings of the National Academy of Sciences 97 (20), 10990-10995, 2000	554	2000
Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017 S Gillessen, G Attard, TM Beer, H Beltran, A Bossi, R Bristow, B Carver, ... European urology 73 (2), 178-211, 2018	539	2018
Consensus report: definition and interpretation of remission in type 2 diabetes MC Riddle, WT Cefalu, PH Evans, HC Gerstein, MA Nauck, WK Oh, ... The Journal of Clinical Endocrinology & Metabolism 107 (1), 1-9, 2022	484	2022
Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019 S Gillessen, G Attard, TM Beer, H Beltran, A Bjartell, A Bossi, A Briganti, ... European urology 77 (4), 508-547, 2020	394	2020
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 S Gillessen, A Omlin, G Attard, JS De Bono, E Efstathiou, K Fizazi, ... Annals of Oncology 26 (8), 1589-1604, 2015	393	2015
A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy MD Galsky, NM Hahn, J Rosenberg, G Sonpavde, T Hutson, WK Oh, ... The lancet oncology 12 (3), 211-214, 2011	372	2011
A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer JP Eder, PW Kantoff, K Roper, GX Xu, GJ Bubley, J Boyden, L Gritz, ... Clinical Cancer Research 6 (5), 1632-1638, 2000	365	2000
Management of hormone refractory prostate cancer: current standards and future prospects WK OH, PW KANTOFF The Journal of urology 160 (4), 1220-1229, 1998	363	1998
Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer D Kaufman, D Raghavan, M Carducci, EG Levine, B Murphy, J Aisner, ... Journal of Clinical Oncology 18 (9), 1921-1927, 2000	335	2000
Castration-resistant prostate cancer: AUA Guideline MS Cookson, BJ Roth, P Dahm, C Engstrom, SJ Freedland, M Hussain, ... The Journal of urology 190 (2), 429-438, 2013	329	2013
The association between germline BRCA2 variants and sensitivity to platinum‐based chemotherapy among men with metastatic prostate cancer MM Pomerantz, S Spisák, L Jia, AM Cronin, I Csabai, E Ledet, AO Sartor, ... Cancer 123 (18), 3532-3539, 2017	303	2017
Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma MD Galsky, GJ Chen, WK Oh, J Bellmunt, BJ Roth, R Petrioli, L Dogliotti, ... Annals of oncology 23 (2), 406-410, 2012	303	2012
Functional enhancers at the gene-poor 8q24 cancer-linked locus L Jia, G Landan, M Pomerantz, R Jaschek, P Herman, D Reich, C Yan, ... PLoS genetics 5 (8), e1000597, 2009	296	2009
Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis S Seng, Z Liu, SK Chiu, T Proverbs-Singh, G Sonpavde, TK Choueiri, ... Journal of clinical oncology 30 (35), 4416-4426, 2012	290	2012
EMT-and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer L Wang, A Saci, PM Szabo, SD Chasalow, M Castillo-Martin, ... Nature communications 9 (1), 3503, 2018	286	2018

Sistem, işlemi şu anda gerçekleştiremiyor. Daha sonra yeniden deneyin.

Makaleler 1–20

Yıllık alıntı sayısı

Mükerrer alıntılar

Birleştirilmiş alıntılar

Katkıda bulunan yazar ekleKatkıda bulunan yazarlar

Takip et

Alıntı yapanlar

Katkıda bulunan yazarlar